Want the latest on Novartis' should-we-or-shouldn't-we asset review?
Leerink Partners analysts met with CEO Joe Jimenez recently, so they can
deliver that and more, including some hints at cost-cutting targets.
As you know, Novartis is analyzing four of its smaller units, with an eye
to either: a., dispose of them in a shareholder-friendly way; or b., somehow
build them into bigger contributors to the bottom line. Those units would be
animal health, vaccines, consumer healthcare and diagnostics.